The first intention of the trial was to determine if Anastrozole could increase the length of “disease-absolutely free survival” to the collaborating clients. Disorder-free of charge survival is described as being the period immediately after prescription drugs and/or therapies are stopped ahead of the affected person’s most cancers returns.